PRL-secreting pituitary adenomas in pregnancy

Journal of Endocrinological Investigation

Volumn 26, Issue 1, 2003, Pages 96-99

  Chiodini, Iacopo ^a   Liuzzi, A ^b  

^a San Giuseppe Hospital   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Pituitary adenoma; Pregnancy; PRL

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROLACTIN;

CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; DATA ANALYSIS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ESTROGEN BLOOD LEVEL; FETUS DEVELOPMENT; FOLLOW UP; GESTATION PERIOD; HIGH RISK PATIENT; HUMAN; HYPOPHYSIS ADENOMA; MEDICAL CARE; NONHUMAN; OUTCOMES RESEARCH; OVULATION; PATIENT MONITORING; POPULATION RESEARCH; PREGNANCY; PROLACTIN RELEASE; PROLACTINOMA; REVIEW; SIDE EFFECT; TERATOGENICITY; TUMOR GROWTH; TUMOR VOLUME;

EID: 0037216794     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345132     Document Type: Review

References (28)

1. Gemzell C., Wang C.F. Outcome of pregnancy in women with pituitary adenomas. Fertil. Steril. 1979, 31: 363-372.
2. Molitch M.E. Disorders of prolactin secretion. Endocrinol. Metab. Clin. North Am. 2001, 30: 585-610.
3. Scheithauer B.W., Sano T., Kovacs K.T., et al. The pituitary gland in pregnancy: A clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc. 1990, 65: 461-464.
4. Harris H., Valcavi R., Artioli C. The influence of estrogens on the sensitivity of prolactin, TSH, and LH, to the inhibitory action of dopamine in hyperprolactinemic patients. In: Mac Leod R.M., Scapagnini U. Thorner M.O. (Eds.), Prolactin Basic and Clinical Correlates. Liviana Press, Padova, 1985, pp. 573-582.
5. Cramer O.M., Parker C.R., Porter J.C. Estrogens inhibition of dopamine release into hypophyseal portal blood. Endocrinology 1979, 104: 419-423.
6. Caron R.W., Deis R.P. Participation of opioid and serotoninergic systems in prolactin secretion induced by hypothalamic action of estradiol. Neuroendocrinology 1996, 64: 124-128.
7. Dericks Tan J.S., Taubert H.D. Elevation of serum prolactin during application of oral contraceptives. Contraception 1976, 14: 1-8.
8. Wingrave S.J., Kay C.R., Vessey M.P. Oral contraceptives and pituitary adenomas. BMJ 1980, 280: 685-686.
9. Davis J.R., Selby C., Jeffcoate W.J. Oral contraceptive agents do not affect serum prolactin in normal women. Clin. Endocrinol. 1984, 20: 427-434.
10. Elias K.A., Weiner R.I. Direct arterial vascularization of estrogen-induced prolactin-secreting anterior pituitary tumors. Proc. Natl. Acad. Sci. USA 1984, 81: 4549-4553.
11. Rijosk H.K., Fahlbush R., Von Werder K. Influence of pregnancies on prolactinomas. Acta Endocrinol. (Copenh) 1982, 100: 333-336.
12. White M.C., Rosenstock J., Anapliotou M. et al. Heterogeneity of prolactine response to oestradiol benzoate in women with prolactinomas. Lancet 1981, 1: 1394-1396.
13. Mornex R., Hugues B. Remission of hyperprolactinemia after pregnancy. N. Engl. J. Med. 1991, 324: 60.
14. Molitch M.E. Pregnancy and the hyperprolactinemic women. N. Engl. J. Med. 1985, 312: 1365-1370.
15. Molitch M.E. Management of prolactinomas during pregnancy. J. Reprod. Med. 1999, 44 (Suppl.): 1121-1126.
16. Lamberts S.W.J., Kliin J.C.M., De Lange S.A. et al. The incidence of complications during pregnancy after treatment of hyperprolactinemia with bromocriptine in patients with neurogically evident pituitary tumors. Fertil. Steril. 1979, 31: 614-619.
17. Bergh T., Nillius S.J., Wide L. Clinical course and outcome of pregnancies in amenhorroeic women with hyperprolactinemia and pituitary tumors. BMJ 1978, 2: 875-870.
18. Magyar D.M., Marshall J.R. Pituitary tumors and pregnancy. Am. J. Obstet. Gynecol. 1978, 132: 739-751.
19. Cunnah D., Besser M. Management of prolactinomas. Clin. Endocrinol. (Oxf.) 1991, 34: 231-235.
20. Raymond J.P., Goldstein E., Konopka P. et al. Follow up of children born on bromocriptine-treated mothers. Horm. Res. 1985, 22: 239-246.
21. Canales E.S., Garcia I.C., Ruiz J.E., et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil. Steril. 1981, 36: 524-526.
22. Turkalj I., Braun P., Krupp P. Surveillance of bromocriptine in pregnancy. J. Am. Med. Assoc. 1982, 247: 1589-1591.
23. Robert E., Musatti L., Piscitelli G., et al. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod. Toxicol. 1996, 10: 333-337.
24. Ciccarelli E., Grottoli S., Gaia D., et al. Long-term treatment with cabergoline, a new long lasting ergoline derivative, in idiopathic or tumorous hyperprolactinemia and outcome of drug-induced pregnancy. J. Endocrinol. Invest. 1997, 20: 547-551.
25. Molitch M.E. Pathologic hyperprolactinemia. Endocrinol. Metab. Clin. North Am. 1992, 21: 877-901.
26. Reilly P.L. Prolactinomas: Surgical results and prognosis. In: Landolt A. M., Vance M.L., Reilly P.L. (Eds.), Pituitary Adenomas. Churchill Livingstone. 1996, 363-368.
27. Brodsky J.B., Cohen E.N., Brown B.W. Jr., et al. Surgery during pregnancy and fetal outcome. Am. J. Obstet. Gynecol. 1980, 138: 1165-1167.
28. Ruiz-Velasco V., Tolis G. Pregnancy in hyperprolactinemic women. Fertil. Steril. 1984, 41: 793-805.